214 related articles for article (PubMed ID: 24294976)
1. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
[TBL] [Abstract][Full Text] [Related]
2. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
3. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
6. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
Moore HM; Gonzalez ME; Toy KA; Cimino-Mathews A; Argani P; Kleer CG
Breast Cancer Res Treat; 2013 Apr; 138(3):741-52. PubMed ID: 23539298
[TBL] [Abstract][Full Text] [Related]
7. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.
Adhikary G; Grun D; Balasubramanian S; Kerr C; Huang JM; Eckert RL
Carcinogenesis; 2015 Jul; 36(7):800-10. PubMed ID: 25969142
[TBL] [Abstract][Full Text] [Related]
8. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
[TBL] [Abstract][Full Text] [Related]
9. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
[TBL] [Abstract][Full Text] [Related]
10. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.
Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R
Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory breast cancer (IBC): clues for targeted therapies.
Fernandez SV; Robertson FM; Pei J; Aburto-Chumpitaz L; Mu Z; Chu K; Alpaugh RK; Huang Y; Cao Y; Ye Z; Cai KQ; Boley KM; Klein-Szanto AJ; Devarajan K; Addya S; Cristofanilli M
Breast Cancer Res Treat; 2013 Jul; 140(1):23-33. PubMed ID: 23784380
[TBL] [Abstract][Full Text] [Related]
12. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.
Arora J; Sauer SJ; Tarpley M; Vermeulen P; Rypens C; Van Laere S; Williams KP; Devi GR; Dewhirst MW
Oncotarget; 2017 Apr; 8(16):25848-25863. PubMed ID: 28460441
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
15. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.
van Vlerken LE; Kiefer CM; Morehouse C; Li Y; Groves C; Wilson SD; Yao Y; Hollingsworth RE; Hurt EM
Stem Cells Transl Med; 2013 Jan; 2(1):43-52. PubMed ID: 23283488
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
17. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
18. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
[TBL] [Abstract][Full Text] [Related]
19. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.
Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL
Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG
Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
